All sponsors

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS15
PHASE 3 / 2-36
RECRUITING3
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO0%

Delay Index: of 6 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
FCN-159
NCT05997602
P2RecruitingLangerhans Cell Histiocytosis; LCH562025-05-14
Drug: Foritinib Succinate
NCT06569420
P3Active, not recruitingNon-Small Cell Lung Cancer; ALK-positive2752025-07-31
Test group (Group A): FCN-159 8 mg, orally, once daily;
NCT05913037
P3Active, not recruitingNeurofibromatosis 1; Plexiform Neurofibroma1672025-08-19 (+2 mo)
FCN-338 + Azacitidine
NCT06858618
P2Active, not recruitingSafety; Antitumor Activity472026-12-01
XH-S004 20 mg
NCT06981091
P2Active, not recruitingNon-Cystic Fibrosis Bronchiectasis2342027-01-08
FXS5626 tablet
NCT07552012
P2RecruitingActive Non-anterior, Non-infectious Uveitis402027-02-28
Luvometinib
NCT07004075
P3Not yet recruitingLow-grade Glioma; Pediatric Low-grade Gliomas1022027-04-30
FXS6837 Dose 1
NCT07502638
P2Not yet recruitingIgAN602027-09-12
Intervention1: FXS5626 Tablets
NCT07840820
P2/3Not yet recruitingNon-segmental Vitiligo4802027-11-10
XS-03-II201
NCT06936527
P1/2Enrolling by invitationColorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation1022028-04-30
FXS6837 Capsule
NCT07747090
P3Not yet recruitingParoxysmal Nocturnal Hemoglobinuria902028-05-05
FXS6837 Capsule
NCT07914894
P3Not yet recruitingParoxysmal Nocturnal Hemoglobinuria202028-05-17
luvometinib + anlotinib
NCT07562581
P2RecruitingNon-small Cell Lung Caner; KRAS-mutated482029-06
Luvometinib Tablets
NCT07024394
P1/2Not yet recruitingNeurofibromatosis 1; Plexiform Neurofibroma652029-09-23
FXS6837 Capsule
NCT07750665
P2Not yet recruitingPrimary IgAN602029-11-13